AMNOG farewell

12.11.2010 14:23

New balance between innovation and affordability of medicines?

“The Pharmaceutical Market Reorganization Act (AMNOG) passed today in the Bundestag will lead to a significant deterioration in supply and serious effects on research in the pharmaceutical sector,” says the BPI.

“With AMNOG, politicians have missed the opportunity to strengthen therapy safety and create reliable framework conditions for generic drug manufacturers in Germany,” complains Progenerika.

“The pharmaceutical market reorganization law passed yesterday by the government coalition set off alarm bells for the Rhineland-Palatinate Pharmacists’ Association,” report the pharmacists

The reactions of market partners to the AMNOG just passed by the Bundestag are just as diverse as the discussion, from the idea to the bill to the last meeting of the Health Committee. Federal Health Minister Dr. Philipp Rösler clear the way “for fair competition and a stronger focus on the well-being of patients”. Following the decision, Rösler said: “We are creating a new balance between innovation and affordability of medicines. Additional benefits and competition will determine the price in the future. We are also relieving doctors of bureaucratic burdens and providing citizens with more information through independent patient advice.” But this is and remains controversial.

November 12, 2010